share_log

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

Benzinga ·  Nov 27, 2023 22:00

Ladenburg Thalmann analyst Ahu Demir initiates coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces Price Target of $7.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment